A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

Found in the Journal of Nuclear Medicine.

By automatically quantifying tumour burden, the new tool can be useful for assessing patient risk, predicting treatment response, and estimating survival.

“Automatic detection and characterisation of cancer are important clinical needs to enable early treatment,” said Kevin H. Leung, PhD, research associate at Johns Hopkins University School of Medicine in Baltimore, Maryland.

“Most AI models that aim to detect cancer are built on small to moderately sized datasets that usually encompass a single malignancy and/or radiotracer. This represents a critical bottleneck in the current training and evaluation paradigm for AI applications in medical imaging and radiology.”

To address this issue, researchers developed a deep transfer learning approach (a type of AI) for fully automated, whole-body tumour segmentation and prognosis on PET/CT scans.

Data from 611 FDG PET/CT scans of patients with lung cancer, melanoma, lymphoma, head and neck cancer, and breast cancer, as well as 408 PSMA PET/CT scans of prostate cancer patients were analysed in the study.

The AI approach automatically extracted radiomic features and whole-body imaging measures from the predicted tumour segmentations to quantify molecular tumour burden and uptake across all cancer types.

Quantitative features and imaging measures were used to build predictive models to demonstrate prognostic value for risk stratification, survival estimation, and prediction of treatment response in patients with cancer.

“In addition to performing cancer prognosis, the approach provides a framework that will help improve patient outcomes and survival by identifying robust predictive biomarkers, characterising tumour subtypes, and enabling the early detection and treatment of cancer,” noted Leung.

“The approach may also assist in the early management of patients with advanced, end-stage disease by identifying appropriate treatment regimens and predicting response to therapies, such as radiopharmaceutical therapy.”

Leung noted that in the future generalisable, fully automated AI tools will play a major role in imaging centers by assisting physicians in interpreting PET/CT scans of patients with cancer.

The deep learning approach may also lead to the discovery of important molecular insights about the underlying biological processes that may be currently understudied in large-scale patient populations.

Source: Society of Nuclear Medicine and Molecular Imaging